title: [Experimental studies on antitumor activity of new recombinant human tumour necrosis factor in nude mice bearing nasopharyngeal carcinoma].
abstract: OBJECTIVE
  Nude mice model bearing nasopharyngeal carcinoma were established using nasopharyngeal squamous carcinoma cell line (CNE-2).
  
  
  METHODS
  New recombinant human tumor necrosis factor (NrhTNF-alpha) and carboplatin were administered locally or systemically, single or in combination. The microstructural and ultra-micro-structural changes of carcinoma after administration of NrhTNF-alpha were observed under light and electron microscopes.
  
  
  CONCLUSIONS
  1. After treatment, the tumor showed hemorrhage, necrosis, regression, the survival time was prolonged. 2. Locally administered NrhTNF-alpha had more significant antitumor effect than intravenously administered of NrhTNF-alpha. 3. There is a notable synergistic antitumor effect by the combination use of NrhTNF-alpha and carboplatin. 4. Microscopy showed that cell changes mostly took place in plasma especially in mitochondria and endoplosmic reticula. The mitochondria were highly bloated. Besides, some nuclei were condensed and fragmented, resulted in cell death. These studies provide experimental basis for biological treatment of nasopharyngeal carcinoma.
authors.affiliation: Nanjing Hospital of PLA Air Force, Nanjing 210002.
authors.forename: W
authors.initials: W
authors.lastname: Dong
authors.forename: R
authors.initials: R
authors.lastname: Zhou
authors.forename: S
authors.initials: S
authors.lastname: Zhou
mesh_terms: D000818:Animals; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000008:administration & dosage; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
chemical_list: D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016190:Carboplatin